The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2014 | ASH 2014: Phase Ib study of daratumumab in combination with backbone regimens in myeloma
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Maria-Victoria Mateos discusses an open-label, multicentre, phase Ib study of the safety, tolerability and dose regimen of the anti-CD38 monoclonal antibody, daratumumab, in combination with backbone regimens in patients with multiple myeloma. Backbone regimens include bortezomib-dexamethasone, bortezomib-thalidomide-dexamethasone, bortezomib-melphalan-prednisone and pomalidomide-dexamethasone.
